Table 2

Integrated analysis comparing the number of patients who had asthma exacerbations according to three definitions among patients who received zafirlukast 20 mg twice daily or placebo

Exacerbations that: Zafirlukast
(n = 972)
Placebo
(n = 692)
Odds ratio 95% confidence interval p value p value
(Breslow-Day test)
Led to withdrawal26 (2.7) 38 (5.5)0.450.26 to 0.760.0030.833
Required additional asthma treatment33 (3.4)53 (7.7)0.470.30 to 0.740.0010.477
Required oral steroid treatment31 (3.2)45 (6.5)0.530.32 to 0.860.0100.702
  • Values are no. (%).